Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018
April 18 2018 - 8:00AM
Galectin Therapeutics Inc. (NASDAQ:GALT), the
leading developer of therapeutics that target galectin proteins,
today announced that Peter G. Traber, M.D., the Company’s CEO and
CMO, has been selected as an expert speaker and will participate in
multiple presentations, including a keynote session, during the 2nd
Annual NASH Summit being held at the Revere Hotel Boston Common in
Boston on April 23-25, 2018. Details of Dr. Traber’s sessions
can be found below.
- Tuesday, April 24, 2018 5:15 p.m.: Panel Discussion -
Non-Invasive Biomarkers - How Near Are We?
- Wednesday, April 25, 2018 3:30 p.m.: Keynote – Clinical Trials
& Endpoints in NASH Cirrhosis
The NASH Summit is the industry’s
most comprehensive conference on drug development for non-alcoholic
steatohepatitis (NASH) focused on drug discovery through late stage
clinical development. It brings together thought leaders from
across the industry to give detailed presentations across multiple
streams of learning in the NASH sector.
Positive Results in NASH Cirrhosis
Galectin Therapeutics recently completed a Phase 2b clinical trial
(NASH-CX) on GR-MD-02, the Company’s proprietary polysaccharide
pharmaceutical preparation that inhibits galectin proteins. There
were statistically significant and clinically relevant positive
effects of GR-MD-02 on portal hypertension (hepatic venous pressure
gradient or HVPG) and other liver biopsy parameters in patients
with NASH cirrhosis without esophageal varices following one year
of therapy. Patients without esophageal varices comprise about 50
percent of the total population of patients with NASH cirrhosis,
and is estimated to be 2.5 million people in the United States.
This group of patients is readily diagnosed by endoscopy which is
already part of the standard of care for patients with NASH
cirrhosis. The drug was well tolerated during this one-year
trial. The Company believes that this is the first
randomized clinical trial of any drug to demonstrate clinically
meaningful positive effects in this important group of patients.
Full details of Galectin’s NASH-CX trial can be found in a
supplemental slide deck of the Galectin corporate presentation on
the homepage of its website. About Galectin
Therapeutics Galectin Therapeutics is dedicated to
developing novel therapies to improve the lives of patients with
chronic liver and skin diseases and cancer. Galectin’s lead drug
(GR-MD-02) is a carbohydrate-based drug that inhibits the
galectin-3 protein which is directly involved in multiple
inflammatory, fibrotic, and malignant diseases. The lead
development program is in non-alcoholic steatohepatitis (NASH) with
cirrhosis, the most advanced form of NASH related fibrosis. This is
the most common liver disease and one of the largest drug
development opportunities available today. Additional development
programs are in treatment of severe atopic dermatitis,
moderate-to-severe plaque psoriasis, and in combination
immunotherapy for advanced melanoma and other malignancies.
Galectin seeks to leverage extensive scientific and development
expertise as well as established relationships with external
sources to achieve cost-effective and efficient development.
Additional information is available at
www.galectintherapeutics.com. Contact: Jack
Callicutt, Chief Financial Officer (678) 620-3186
ir@galectintherapeutics.com. Galectin Therapeutics and its
associated logo is a registered trademark of Galectin Therapeutics
Inc.
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Apr 2023 to Apr 2024